Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 2/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7394092 | 0.85 | CASP3 (0.51) | CASP3MDM4TP53KMT2ATNF | |
| SCHEMBL7401573 | 0.85 | CASP3 (0.51) | CASP3MDM4TP53KMT2ATNF | |
| SCHEMBL7399610 | 0.85 | CASP3 (0.51) | CASP3MDM4TP53KMT2ATNF | |
| SCHEMBL7399615 | 0.85 | CASP3 (0.51) | CASP3MDM4TP53KMT2ATNF | |
| SCHEMBL7394094 | 0.85 | CASP3 (0.51) | CASP3MDM4TP53KMT2ATNF | |
| SCHEMBL12972480 | 0.84 | TLR2 (0.43) | CASP3MDM4TP53 | |
| SCHEMBL14047810 | 0.84 | CASP3 (0.51) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL8009538 | 0.84 | CASP3 (0.53) | CASP3MDM4TP53KMT2ATNF | |
| SCHEMBL9186701 | 0.83 | MDM4 (0.59) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL8653790 | 0.83 | MDM4 (0.59) | CASP3MDM4TP53KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552133-B2 | Controlled polymerisation process | SYNGENE LIMITED (AU) | 2013-10-08 | — | — | US | disclosed |
| US-20100331521-A1 | Controlled Polymerisation Process | MONASH UNIVERSITY (AU) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331521-A1 | Controlled Polymerisation Process | MSN, LNPEP, NGLY1 | CASP3 1619/4885MDM4 168/4885TP53 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.